We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Evidence to Practice |

Effectiveness and Value of Treatment Options for Obesity—A Report for the California Technology Assessment Forum

Daniel A. Ollendorf, PhD1; Christopher G. Cameron, PhD2,3; Steven D. Pearson, MD, MSc1
[+] Author Affiliations
1Institute for Clinical and Economic Review, Boston, Massachusetts
2Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
3now at Cornerstone Research Group Inc, Burlington, Ontario, Canada
JAMA Intern Med. 2016;176(2):247-248. doi:10.1001/jamainternmed.2015.7189.
Text Size: A A A
Published online


This article summarizes an evidence report for the California Technology Assessment Forum about the comparative effectiveness and value of surgical, device, and new drug vs lifestyle, diet, and existing drug treatment of obesity.

Article InformationCorresponding Author: Daniel A. Ollendorf, PhD, Institute for Clinical and Economic Review, One State Street, 10th Floor, Boston, MA 02109 (dollendorf@icer-review.org).

Published Online: January 4, 2016. doi:10.1001/jamainternmed.2015.7189.

Conflict of Interest Disclosures: Dr Cameron has served on an advisory board for Eli Lilly & Co. No other disclosures are reported.

Funding/Support: The CTAF is a program of the Institute for Clinical and Economic Review and is supported by grants from the BlueShield of California Foundation, the California HealthCare Foundation, and the Laura and John Arnold Foundation.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Karen Shore, PhD, Matthew Seidner, Patricia Synnott, MALD, MS, and Anne Loos, MS, of the Institute for Clinical and Economic Review contributed to the development of this manuscript.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Strength of Evidence by Body Mass Index (BMI) Class

BPD, biliopancreatic diversion; DJBL, duodenal-jejunal bypass liner; IGB, intragastric balloon; LAGB, laparoscopic adjustable gastric banding; RYGB, Roux-en-Y gastric bypass; T2DM, type 2 diabetes mellitus; vBloc, vagus nerve blocking system; VSG, vertical sleeve gastrectomy.

Graphic Jump Location





You need to register in order to view this quiz.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles